Jeffrey S. Hatfield
CIK 1609879 · Chief Executive Officer · last filed 2026-05-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
VTAE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VIR | Director | 39,806 | $10.37 | $412.6K | $0 | 7 | 2026-05-28 |
| VRDN | Director | — | $22.98 | — | $0 | 1 | 2021-02-08 |
| Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Director | — | — | — | $0 | 3 | 2020-05-22 |
| LIFE | Director | — | $43.24 | — | $0 | 5 | 2020-05-08 |
| Larimar Therapeutics, Inc. (ZFGN) Delisted | Chief Executive Officer | — | — | — | $0 | 4 | 2019-01-24 |
| INVIVO THERAPEUTICS HOLDINGS CORP. (NVIV) Delisted | Director | — | $0.32 | — | $0 | 2 | 2018-01-23 |
| Vitae Pharmaceuticals, Inc (VTAE) Delisted | Chief Executive Officer | 244,996 | — | — | -$1.42M | 10 | 2016-10-25 |
| AMBIT BIOSCIENCES CORP (AMBI) Delisted | Director | — | $0.54 | — | $0 | 1 | 2014-11-12 |
Recent Filings · Page 2 of 4
33 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-06-21 | Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-05-10 | LIFE | Grant (A) | — | $0 | EDGAR |
| 2019-01-24 | Larimar Therapeutics, Inc. (ZFGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-28 | Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-05-17 | LIFE | Grant (A) | — | $0 | EDGAR |
| 2018-02-23 | Larimar Therapeutics, Inc. (ZFGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-01-23 | INVIVO THERAPEUTICS HOLDINGS CORP. (NVIV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-12-29 | Larimar Therapeutics, Inc. (ZFGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-10-11 | Larimar Therapeutics, Inc. (ZFGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-05-11 | LIFE | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.